Fabius......actually, its difficult to say why the MNK only included those 3 ANDA's. I don't know if it had as much to do with FDA communications or the fact those are the only ones MNK was interested in for one reason or another.
Angelo, found the dates for when the other 2 need to be approved by December 31,2018. so honestly that is telling me the communications the company has with the FDA they expect to have the approvals by then. at which point why didn't the MNK include Glucaphage as the company clearly was in communication with the FDA and knew they were close to meeting all the requirements? its difficult to say. maybe MNK didn't want Glucaphage?
News 
Market Data 
Discover 
AI
